Dabrafenib plus trametinib show activity in certain patients with colorectal cancer
the ONA take:
The combination of dabrafenib plus trametinib has activity in a subset of patients with BRAF V600-mutant metastatic colorectal cancer (mCRC), a new study published online ahead of print in the Journal of Clinical Oncology has shown.
For the study, researchers enrolled 43 patients with BRAF V600-mutant metastatic colorectal cancer and assigned them to receive dabrafenib 150 mg twice daily plus trametinib 2 mg daily.
Results showed that 12% of patients achieved a partial response or better, including one complete response. Furthermore, 56% of patients achieved stable disease as best confirmed response.
Dabrafenib in combination with trametinib is already indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.
The most common adverse events associated with combination dabrafenib-trametinib therapy are pyrexia, chills, fatigue, rash, nausea, vomiting, diarrhea, abdominal pain, headache, arthralgia, night sweats, decreased appetite, constipation, and myalgia.
The combination is also being studied for the treatment of a variety of other solid tumors, including ovarian cancer, thyroid cancer, and non-small cell lung cancer.
Combination of dabrafenib plus trametinib has activity in a subset of patients with BRAF V600-mutant metastatic colorectal cancer.
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Health Care Expansion Tied to Increased Rates of Surgical Treatment of Thyroid Cancer
- Including a PI3-Kinase Inhibitor with an PARP Inhibitor Improves Tumor Shrinkage in Patients with Resistant Ovarian Cancer
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Family History Does Not Exclude Active Surveillance as Treatment Option for Prostate Cancer
- Beans, Whole Grains in Diet Beneficial for Colorectal Cancer Survivors
- Hormone Refractory Prostate Cancer Responds to Abiraterone Acetate in Some Cases
- Shifts in Cancer Burden for People With HIV Projected
- Tissue Biobank Procurement Consent Should Include Discussion of Confidentiality Risks
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|